17β-Estradiol delivered by three different matrix patches 50 μg/day. A three way cross-over study in 21 postmenopausal women

Maturitas

Volumn 33, Issue 1, 1999, Pages 45-58

  Rohr, Uwe D ^a   Nauert, Christian ^b   Stehle, Brigitte ^c  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b Clinical Research Unit   (Germany)

^c Global Medical Affairs Department   (France)

Author keywords

17 Estradiol; Arcadian rhythm; Estrogen replacement therapy; Matrix patch; Menopause rating scale; Postmenopausal women; Transdermal delivery

Indexed keywords

ESTRADIOL; TRADELIA; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; ESTROGEN THERAPY; FEMALE; HEADACHE; HUMAN; POSTMENOPAUSE; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; SKIN MANIFESTATION; TRANSDERMAL DRUG ADMINISTRATION; BIOAVAILABILITY; BLOOD; COMPARATIVE STUDY; INTRADERMAL DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED;

ADMINISTRATION, CUTANEOUS; ADULT; AGED; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE;

EID: 0033600608     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(99)00039-0     Document Type: Article

References (27)

1. Balfour J.A., Heel R.C. Transdermal estradiol: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of menopausal complaints. Drugs. 40:1990;561-582.
2. Powers M.S., Campbell P., Schenkel L. A new transdermal delivery system for β-Estradiol. J. Control. Rel. 2:1985;89-94.
3. Studd J.W.W., Holland E.F.N., Leather A.T. The dose response of percutaneous estradiol implants on the skeleton of postmenopausal women. Br. J. Obstet. Gyaecol. 101:1994;787-791.
4. Laufer L.R., de Fazio J.L., Lu J.K.L. Estrogen replacement therapy by transdermal estradiol administration. Am. J Obstet. Gynecol. 146:1983;533-539.
5. Corson S.L. A decade of experience with transdermal estrogen replacement therapy: overview of key pharmacologic and clinical findings. Int. J. Fertil. 38:1993;79-91.
6. Nichols K.C., Schenkel L., Benson H. 17ß-estradiol for postmenopausal estrogen replacement therapy. Obstet. Gynecol. Surv. 39:1984;230-245.
7. Kuhl H. Pharmacokinetics of oestrogens and progesterons. Maturitas. 12:1990;171-196.
8. Aedo A.R., Landgren B.M., Diczfalusy E. Pharmacokinetics and biotransformation of orally administered estrone sulfate and estradiol valerate in post-menopausal women. Maturitas. 12:1990;333-343.
9. Erpecum K.J., van Berge Hengouwen G.P., Verschoor L., Stoelwinder B., Willekens F.L.H. Different hepatobiliary effects of oral and transdermal estradiol in postmenopausal women. Gastroenterology. 100:1991;482-488.
10. Rohr U.D., Altenburger R., Kissel T. Pharmacokinetics of the transdermal reservoir system delivering β-estradiol: in vitro/in vivo correlation. Pharm. Res. 15:1998;877-882.
11. Setnikar I., Rovati L.C., Vens-Cappell B., Hilgenstock C. Bioavailability of estradiol from two transdermal patches. Drug Res. 46:1996;307-310.
12. Le Roux Y., Borg M.L., Sibille M.J., Thebault R., Douin M.J., Djebbar F., Dain M.P. Bioavailability study of Menorest, a new estrogen transdermal delivery system, compared with a transdermal reservoir system. Clin. Drug Invest. 10:1995;172-178.
13. Rohr U.D., Nauert C., Ehrly A.M. Kinetik eines neuen Pflasters zur transdermalen Applikation von 17β-Estradiol. Zentralbl. Gynakol. 117:1995;531-539.
14. Borg M.L., Gimona A., Renoux A., Douin M.J., Djebbar F., Panis-Rouzier R. Pharmacokinetics of estradiol and estrone following repeated administration of Menorest™, a new estrogen transdermal delivery system, in menopausal woman. Clin. Drug Invest. 10:1995;96-103.
15. Guichard J.P., Sauron R., Dutertre J.P., Tanner T., Woodward A.J., Dewland P. A pilot study of the comparative bioavailability of estradiol from two different estradiol transdermal systems: Oesclin™ 50 and Systen™ 50. Curr. Ther. Res. 56:1995;1022-1032.
16. Blacker C., Brion N., Caulin F., Mayolle C., Reginster J.Y., Regnard A., Scholler R. Plasma concentration of estradiol after transdermal administration of Systen 50 (Evorel™ or Menorest™ 50). Clin. Drug. Invest. 6:1996;339-346.
17. Rohr U.D., Ehrly A., Kuhl H. Plasma profiles of transdermal 17β-Estradiol delivered by two different matrix patches: a four-way cross over study in postmenopausal women. Drug Res. 47(I):1997;761-767.
18. Muller P, Botta L, Ezzet F. Bioavailability of estradiol from a new matrix and a conventional reservoir-type transdermal therapeutic system Eur J Clin Pharmacol 1996;51:327-330.
19. Yalow R. Odell W.D., Daughaday W.H. Principles of Competitive Protein Binding Assays. 1971;1-9 J.B. Lippincott, Philadelphia.
20. Canez M.S. Progesterons and estrogens. Infert. Reprod. Med. North Am. 3:1992;59-78.
21. Rowland M., Tozer T.N. Clinical Pharmacokintics - Concepts and Applications. 1980;Lea and Febinger, Philadelphia, PA.
22. SAS Language. Reference, Version 6, First Edition. Cary, NC: SAS Institute, 1990.
23. Schiurmann D.J. A comparison of the two one sided tests procedures and the power approach for assessing equivalnece of average bioavailability. J. Pharmacokinet. Biopharm. 15:1987;657-680.
24. Wellek S. Statistische Methoden zum Nachweis von Äquivalenz. Gustav Fischer Verlag, 1994.
25. Hauser GA, Huber H, Keller PJ, Lauritzen C, Schneider HPG. Zbl. Gynäkol 1995;116:16-22.
26. Yu Z., Mazer N. Transdermal testosterone administration in hypogonodal men: comparison of pharmacokinetics at different sites of application. J. Clin. Pharmacol. 37:1997;1129-1138.
27. John VA, Ramirez M, Good WR. Bioavailability of estradiol from a new estradiol transdermal delivery system (0.1 mg/day) compared with estraderm 0.1 (0.1 mg/day). Abstract of the 8th International Congress on the Menopause, Sydney Australia, 1996.